Skip to content

Single-cell Transcriptomic Profiling of MASH-HCC Development

  • Barbora Krajnikova

Background & aim: Cellular-level insights into metabolic associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC) have been limited by bulk RNA-sequencing, which masks rare or tumor-relevant populations. Here, we applied single-cell transcriptomics to characterize liver cell-specific transcriptome changes…

Read more

Comparative anti-fibrotic efficacy of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

  • Allison Butt

Background & aim: Resmetirom (RES, THR-βR agonist) has recently been FDA-approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Other drug concepts are in late-stage clinical development for MASH, including semaglutide (SEMA, GLP1R agonist), tirzepatide (TZP, GLP1R-GIPR co-agonist) and efruxifermin…

Read more
Back To Top